RPI ID: 2020-082-401 / 2020-082-601 / 2020-082-602
Innovation Summary:
Compositions containing sulfated polysaccharides such as pentosan polysulfate and mucopolysaccharide polysulfate are designed to inhibit SARS-CoV-2 by blocking viral entry and replication. These formulations are intended for mucosal delivery via nasal spray or aerosol, enabling localized antiviral action at the site of infection. The applications differ in their formulation refinements, delivery mechanisms, and dosing strategies to optimize efficacy and scalability. The therapeutic mechanism targets spike protein binding and supports both prophylactic and therapeutic use.
Challenges / Opportunities:
Current antiviral treatments often act post-infection and may not prevent initial viral entry. These formulations offer a preventative strategy that can be deployed rapidly in outbreak scenarios. They support flexible dosing and delivery formats, including intranasal and inhalable options. The technology is compatible with pharmaceutical manufacturing pipelines and may be extended to other respiratory viruses.
Key Benefits / Advantages:
✔ Blocks viral entry at mucosal surfaces
✔ Supports prophylactic and therapeutic use
✔ Adaptable to emerging variants
✔ Scalable for global deployment
✔ Compatible with nasal and aerosol delivery
Applications:
• COVID-19 prevention
• Respiratory virus treatment
• Pandemic preparedness
Keywords:
#antiviraltherapy #sulfatedpolysaccharides #nasaldelivery #covid19 #respiratoryhealth #pandemicresponse
Intellectual Property:
US Application 17/915783, US20230201249A1 filed 29-Sep-2022;
US Application 18/597050, US20250114394A1 filed 06-Mar-2024;
US Application 18/899285, US20250090572A1 filed 27-Sep-2024
